Table 2.
Clinical, technical and safety outcomes.
|
Patients with CAD (n = 74) |
Patients with ACAO (n = 92) |
Patients without CAD or ACAO (n = 1398) |
P-value CAD vs. ACAO |
P-value CAD vs. without CAD or ACAO |
|
|---|---|---|---|---|---|
| CLINICAL | |||||
| Delta-NIHSS (mean [sd]) | −5 (7) | −1 (9) | −4 (8) | 0.03 | 0.62 |
| NIHSS follow up (24−48 h) (median [IQR]) | 10 [4–15] | 14 [5–20] | 11 [4–18] | 0.10 | 0.63 |
| mRS score at 90 days (median [IQR])a | 2 [2–4] | 4[2–6] | 3 [2–6] | 0.01 | 0.01 |
| mRS score at 0−2 at 90 days (%) | 36 (51.4) | 27 (30.0) | 486 (37.3) | 0.01 | 0.02 |
| Mortality within 90 days (%) | 8 (11.4) | 27 (30.0) | 368 (28.2) | 0.01 | 0.01 |
| TECHNICAL | |||||
| Duration procedure (median [IQR]) | 74 [51–99] | 80 [57–115] | 65 [40–90] | 0.35 | 0.01 |
| New thrombus different vascular territory – no. (%) | 4 (22.2) | 9 (39.1) | 74 (25.6) | 0.41 | 0.97 |
| Successful recanalization (%)b | 33 (47.1) | 38 (46.9) | 792 (58.4) | 1.00 | 0.08 |
| SAFETY | |||||
| Progression of ischemic stroke (%) | 9 (12.2) | 15 (16.3) | 163 (11.7) | 0.60 | 1.00 |
| Symptomatic intracranial hemorrhage (%)c | 4 (5.4) | 10 (10.9) | 83 (5.9) | 0.33 | 1.00 |
a
Modified Rankin scale score was assessed at 90 days after stroke onset.
b
mTICI ≥ 2B, score of 0 indicates no perfusion or anterograde flow beyond occlusion site, 1: penetration of contrast but not perfusion, 2A: some perfusion <50% of vascular territory, 2B: substantial perfusion ≥50%, 3: complete perfusion of vascular territory.
c
Clinical deterioration due to intracranial hemorrhage defined by the Heidelberg bleeding classification.